 | This article's lead section may be too long. (January 2021) |
Anil Koul | |
|---|---|
 | |
| Born | 1 June 1972 India |
| Alma mater | Max-Planck Institute for Biochemistry (MPI), Munich Germany & CSIR-IGIB Delhi and Delhi University, India |
| Awards | American Chemical Society (ACS) - Heroes of Chemistry Award (2020); Sun Pharma Research Award (2017); Johnson Medal (2013); Swiss-TB prize (2005) |
| Scientific career | |
| Institutions | Institute of Microbial Technology, Chandigarh 160036, India. LSHTM, London, UK. |
Anil Koul (born 1 June 1972) is a scientist and former Director of the CSIR-Institute of Microbial Technology (IMTECH),[1] a premier biomedical and biotechnology research institution under Council of Scientific and Industrial Research (CSIR) under Ministry of Science and Technology, Govt. of India.
Anil is currently a member of scientific advisory board of CSIR, a high powered committee for scientific management of CSIR organization, chaired by principal scientific adviser to the Prime Minister, Prof. Vijay Raghavan.
Anil has more than 18 years of pharmaceutical R&D expertise and currently is vice president and Head of Global Public Health discovery at Johnson & Johnson (J&J). He is member of Board of Directors of Janssen Pharmaceutica NV, the European subsidiary of J&J.
Additionally, Anil was recently appointed as Professor of Translational Discovery at London School of Hygiene and Tropical Medicine (LSHTM), where he will set up a laboratory of Translational drug discovery.[2]
Anil's major scientific career achievement is his key role in discovery and development of new tuberculosis drug Bedaquiline - the first drug to be approved in the last 45 years for treatment of drug-resistant tuberculosis.
- ^ Kanwar, Shimona (13 August 2016). "From Belgium to city for Imtech". The Times of India. Retrieved 14 June 2018.
- ^ "LSHTM". LSHTM.